Cerevel Therapeutics Announces Pricing of $450 Million Public Offering

Cerevel Therapeutics Holdings, Inc. Announces Pricing of Public Offering for Advancing Neuroscience Disease Research

Cerevel Therapeutics Holdings, Inc., a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, announced that the pricing of its previously announced underwritten public offering of 19,728,189 shares of its common stock at a public offering price of $22.81 per share, or approximately $450 million of shares of its common stock. In addition, Cerevel granted the underwriters a 30-day option to purchase up to an additional 2,959,228 shares of its common stock at the public offering price, less underwriting discounts and commissions. The offering is expected to close on October 16, 2023, subject to customary closing conditions.

Goldman Sachs & Co. LLC is acting as the lead book-running manager for the offering. Stifel, Nicolaus & Company, Incorporated is also acting as a book-running manager for the offering. Siebert Williams Shank & Co., LLC is acting as co-manager for the offering.

Cerevel estimates that the net proceeds from the offering of common stock, after deducting underwriting discounts and commissions and estimated offering expenses payable by Cerevel, will be approximately $433.6 million (or approximately $498.7 million if the underwriters exercise in full their option to purchase additional shares).

A registration statement relating to the offering of common stock was filed with the Securities and Exchange Commission (“SEC”) on November 8, 2022 and is effective. 

The offering of common stock is being made only by means of a prospectus supplement and accompanying prospectus. Copies of the prospectus supplement and the accompanying prospectus may be obtained.

Published on : 12th October, 2023